Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers

Familial Cancer

Volumn 9, Issue 3, 2010, Pages 313-319

  Pichert, G ^a   Jacobs, C ^a   Jacobs, I ^b   Menon, U ^b   Manchanda, R ^b   Johnson, M ^b   Hamed, H ^a   Firth, C ^a   Evison, M ^c   Tutt, A ^a   De Silva, L ^d   Langman, C ^d   Izatt, L ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c Dimbleby Cancer Care Centre   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

BRCA1; BRCA2; Breast cancer; Cancer risk management; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL TRIAL; FAMILIAL CANCER; FEMALE; FOLLOW UP; HETEROZYGOTE; HISTOPATHOLOGY; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; MASTECTOMY; MEDICAL PRACTICE; MEDICAL SPECIALIST; MULTIDISCIPLINARY ONE STOP FOLLOW UP CLINIC; OVARY; OVARY CANCER; PATIENT COUNSELING; PERITONEUM LAVAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE; UTERINE TUBE;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CLINICAL TRIALS AS TOPIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK MANAGEMENT; YOUNG ADULT;

EID: 78650197696     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-010-9333-x     Document Type: Article

References (22)

1. Slattery ML, Kerber RA (1993) A comprehensive evaluation of family history and breast cancer risk. JAMA 270:1563-1568
2. Colditz GA, Willett WC, Hunter DJ et al (1993) Family history, age and risk of breast cancer. JAMA 270:338-343
3. Easton DF, Breast Cancer Linkage Consortium et al (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am Hum Gen 56:256-271
4. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care (partial update of CG14). http://guidance.nice.org.uk/page.aspx?o=CG14. Cited 24 Aug. 2009
5. UK Clinical Research Network: Portfolio Database. http://pfsearch. ukcrn.org.uk/StudyDetail.aspx?TopicID=1&StudyID=1069. Cited 24 Aug. 2009
6. Epidemiological Study of Familial Breast Cancer. http://www.srl.cam.ac. uk/genepi/embrace/embrace-home.html. Cited 24 Aug. 2009
7. http://www.cceb.upenn.edu/pages/prose/. Cited 24 Aug. 2009
8. IMPACT. http://impact-study.co.uk/en/researchers/home. Cited 24 Aug. 2009
9. IBIS. http://www.ibis-trials.org/index.php. Cited 24 Aug. 2009
10. BRCA trial. http://www.breakthroughresearch.org.uk/clinical-trials- clinical-researchers/clinical-trials/brca-trial/index.html. Cited 24 Aug. 2009
11. American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21(12):2397-2406
12. Bernadette A, Heemskerk-Gerritsen M, Brekelmans CTM et al (2007) Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long term experiences at the Rotterdam family cancer clinic. Ann Surg Oncol 14(12):3335-3344
13. Rebbeck TR, Lynch HT, Neuhausen SL, Prevention and Observation of Surgical End Points Study Group et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616-1622
14. Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615
15. Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372
16. Piek JM, Torrenga B, Hermsen B et al (2003) Histopathological characteristics of BRCA1-and BRCA2-associated intraperitoneal cancer: a clinic based study. Fam Cancer 2(2):73-78
17. Callahan MJ, Crum CP, Medeiros F et al (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25(25):3985-3990
18. Powell CB, Kenley E, Chen L et al (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23(1):127-132
19. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al (2008) International variation of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022
20. Meijers Heijboer H, Brekelmans CT, Menke-Pluymers M et al (2003) Use of genetic testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21:1675-1681
21. http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-091261. Cited 7 Sept 2009
22. Bancroft E, Ardern-Jones A, McReynolds K et al (2007) A description of the first oncogenetic clinic for BRCA1/2 mutation carriers in London: The Carrier Clinic. 57th Annual Meeting of the American Society of Human Genetics 390/T